Clinical Trials Directory

Trials / Unknown

UnknownNCT05676593

Interest of FSL 2 in Recently Diagnosed Type 2 Diabetic Patients

Interest of Freestyle Libre 2 as a Tool for Therapeutic Education in Recently Diagnosed Type 2 Diabetics Patients

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
40 (estimated)
Sponsor
University Hospital, Montpellier · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Therapeutic patient education (TPE) is a key element in the management of people living with type 2 diabetes. The benefit of therapeutic education (TPE) has been clearly established on glycaemic control. Continuous interstitial glucose monitoring (CGM) can be considered as a TPE tool for people living with diabetes. A direct reading of the effects of diet and physical activity on glycaemic levels could have an impact on the initiation and maintenance of therapeutic lifestyle modifications. The investigators therefore propose a prospective randomised study in 2 arms : * a group of people living with diabetes receiving standard TPE vs * a group of people living with diabetes receiving standard TPE + FSL 28 days Ourmain objective is to determine the benefit of CGM on HbA1c at 3 months between 2 arms

Detailed description

Main objective to the investigators is to determine the benefit of continuous interstitial glucose monitoring (by fresstyle 2) for 28 days coupled with standard TPE (Patient Therapeutic Education) vs standard TPE alone in newly diagnosed type 2 diabetics on HbA1c at 3 months. The secondary objectives are to evaluate the effect of the TPE coupled with FSL vs TPE alone on : * HbA1c at 6 months (assessment of persistence or not of a remote effect) * weight change at 3 and 6 months * other cardiovascular risk factors : variation in blood pressure, lipid profil at 3 and 6 months * eating behaviour/ eating habits at 3 and 6 months * treatment satisfaction, anxiety and quality of life scores

Conditions

Interventions

TypeNameDescription
DEVICEFreestyle Libre 2The FSL will be placed on patient for 28 days to measure interstitial glucose
OTHERTherapeutic educationTherapeutic education

Timeline

Start date
2023-05-03
Primary completion
2024-11-03
Completion
2024-12-03
First posted
2023-01-09
Last updated
2023-11-07

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT05676593. Inclusion in this directory is not an endorsement.